Rilapladib

Rilapladib Uses, Dosage, Side Effects, Food Interaction and all others data.

Rilapladib is the third genomics-derived small molecule drug arising from the Human Genome Sciences-GlaxoSmithKline collaboration to enter clinical development. It is a lipoprotein-associated phospholipase A2 (Lp-PLA2) inhibitor. Lp-PLA2 is an enzyme associated with the formation of atherosclerotic plaques.

Trade Name Rilapladib
Generic Rilapladib
Rilapladib Other Names Rilapladib
Type
Formula C40H38F5N3O3S
Weight Average: 735.81
Monoisotopic: 735.255404085
Groups Investigational
Therapeutic Class
Manufacturer
Available Country
Last Updated: September 19, 2023 at 7:00 am
Rilapladib
Rilapladib

Uses

Investigated for use/treatment in atherosclerosis and cardiovascular disorders.

How Rilapladib works

Rilapladib is a Lp-PLA2 inhibitor. Lp-PLA2 has been found to be enriched in the highly atherogenic lipoprotein subfraction of small dense LDL, which is susceptible to oxidative modification. Moreover, enzyme levels are increased in patients with hyperlipidaemia, stroke, Type 1 and Type 2 diabetes mellitus, as well as in post-menopausal women. As such, plasma Lp-PLA2 levels tend to be elevated in those individuals who are considered to be at risk of developing accelerated atherosclerosis and clinical cardiovascular events. Thus, inhibition of the Lp-PLA2 enzyme would be expected to stop the build up of this fatty streak (by inhibition of the formation of lysophosphatidylcholine), and so be useful in the treatment of atherosclerosis.

Innovators Monograph

You find simplified version here Rilapladib

*** Taking medicines without doctor's advice can cause long-term problems.
Share